Mankind Pharma Sees Sharp Open Interest Surge Amid Volatile Trading

Open Interest and Volume Dynamics

The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives rose sharply by 4,618 contracts, a 26.6% increase from the previous figure of 17,362 to 21,980. This substantial rise in OI was accompanied by a robust trading volume of 34,738 contracts, indicating active participation from traders and investors in the futures and options market.

In monetary terms, the futures segment alone accounted for a value of approximately ₹19,636.88 lakhs, while the options segment’s value was significantly higher at ₹15,192.41 crores, culminating in a total derivatives value of ₹22,076.13 lakhs. Such elevated volumes and open interest levels suggest that market participants are positioning themselves aggressively, possibly anticipating a directional move in the stock.

Price Action and Volatility Context

Mankind Pharma’s underlying share price closed near its 52-week low, just 1.4% above the low of ₹2,046.8, closing at ₹2,084 on the day. The stock underperformed its Pharmaceuticals & Biotechnology sector by 3.84%, while the broader Sensex managed a modest gain of 0.17%. Intraday, the stock touched a low of ₹2,057.1, marking a steep 4.88% decline from the previous close, and exhibited high volatility with an intraday range of 5.08% based on weighted average price calculations.

Notably, the weighted average price showed that a greater volume of trades occurred closer to the day’s low, signalling selling pressure or bearish sentiment among market participants. The stock is trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – reinforcing the prevailing downtrend and technical weakness.

Investor Participation and Liquidity

Investor engagement has risen sharply, with delivery volumes on 3 February reaching 4.16 lakh shares, a 93.43% increase compared to the five-day average delivery volume. This surge in delivery volume indicates that investors are not only trading derivatives but also taking or giving actual share delivery, reflecting conviction in their positions.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹1.97 crore based on 2% of the five-day average traded value. This liquidity profile facilitates smooth execution of large orders without significant market impact, which is crucial for institutional investors and large traders.

Market Positioning and Potential Directional Bets

The sharp increase in open interest alongside heavy volumes and price weakness suggests that traders may be building bearish positions or hedging existing long exposures. The fact that the stock is trading near its 52-week low and below all major moving averages supports the view that market participants are cautious or negative on near-term prospects.

However, the sizeable delivery volumes indicate that some investors might be accumulating shares at these lower levels, possibly anticipating a medium to long-term recovery. The divergence between derivatives activity and underlying share delivery volumes points to a complex market dynamic where short-term traders and long-term investors are simultaneously active but with differing outlooks.

Mojo Score and Analyst Ratings

Mankind Pharma currently holds a Mojo Score of 38.0, categorised as a Sell rating, downgraded from a Hold on 19 November 2025. The downgrade reflects deteriorating fundamentals or technical outlook as assessed by MarketsMOJO’s proprietary scoring system. The company’s market capitalisation stands at ₹85,752 crore, classifying it as a large-cap stock, but its Market Cap Grade is rated at 1, indicating limited upside potential relative to peers.

Given the current technical weakness and negative momentum, investors should exercise caution. The stock’s underperformance relative to the sector and Sensex, combined with the surge in open interest, suggests that downside risks remain elevated in the near term.

Sector and Broader Market Comparison

The Pharmaceuticals & Biotechnology sector has been relatively stable, with a minor 0.17% gain in the Sensex contrasting with Mankind Pharma’s 3.94% decline on the day. This divergence highlights company-specific challenges or profit-taking pressures that are not reflective of the broader sector trend.

Investors should monitor sectoral developments, regulatory changes, and company-specific news closely, as these factors could influence the stock’s trajectory and derivatives market activity going forward.

Investor Takeaway

The recent surge in open interest and volume in Mankind Pharma’s derivatives market signals increased speculative and hedging activity amid a volatile price environment. While the stock’s technical indicators and Mojo Grade suggest caution, the elevated delivery volumes hint at selective accumulation by longer-term investors.

Market participants should closely monitor open interest trends, price action relative to key moving averages, and sector developments to gauge the sustainability of current market positioning. Given the stock’s proximity to its 52-week low and the prevailing downtrend, risk management remains paramount for traders and investors alike.

Outlook

In the near term, Mankind Pharma’s price action and derivatives activity suggest a cautious or bearish stance among traders. However, any positive catalysts such as regulatory approvals, earnings surprises, or sector tailwinds could trigger a reversal in sentiment and open interest dynamics. Until then, the stock remains under pressure with limited upside potential as per current assessments.

Unlock special upgrade rates for a limited period. Start Saving Now →